Diagnostic biomarkers for Alzheimer's disease: a regulatory view

Affiliations

¹ Institute of Psychiatry, Neurology and Neuroscience, London, UK.
² European Medicines Agency, London E14 5EU, UK.
³ European Medicines Agency, London E14 5EU, UK. Electronic address: maria.isaac@ema.europa.eu.

Comment

M T Isaac et al. Lancet Neurol. 2017 Aug.

. 2017 Aug;16(8):580-581.

doi: 10.1016/S1474-4422(17)30223-5. Epub 2017 Jul 11.

¹ Institute of Psychiatry, Neurology and Neuroscience, London, UK.
² European Medicines Agency, London E14 5EU, UK.
³ European Medicines Agency, London E14 5EU, UK. Electronic address: maria.isaac@ema.europa.eu.

No abstract available

Comment on

Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.
Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, Garibotto V, Giannakopoulos P, Gietl A, Hansson O, Herholz K, Jack CR Jr, Nobili F, Nordberg A, Snyder HM, Ten Kate M, Varrone A, Albanese E, Becker S, Bossuyt P, Carrillo MC, Cerami C, Dubois B, Gallo V, Giacobini E, Gold G, Hurst S, Lönneborg A, Lovblad KO, Mattsson N, Molinuevo JL, Monsch AU, Mosimann U, Padovani A, Picco A, Porteri C, Ratib O, Saint-Aubert L, Scerri C, Scheltens P, Schott JM, Sonni I, Teipel S, Vineis P, Visser PJ, Yasui Y, Winblad B. Frisoni GB, et al. Lancet Neurol. 2017 Aug;16(8):661-676. doi: 10.1016/S1474-4422(17)30159-X. Epub 2017 Jul 11. Lancet Neurol. 2017. PMID: 28721928 Review.